Atlas Trials

First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients

Clinical trial NCT04537286 · COMPLETED

Trial details

NCT number
NCT04537286
Sponsor
Fudan University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerTNBC - Triple-Negative Breast Cancer
Start date
2020-08-25
Primary completion
2023-03-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.